Prokidney Corp PROK
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-06-30 |
| Shares Out. | 302,060,000 |
| Website | prokidney.com/ ↗ |
| Phone | 13369997028 |
| Employees | 231 |
| Revenue | $226,000 |
| Gross Profit | $226,000 |
| Net Income | -$42.6M |
| Free Cash Flow | -$150.1M |
| Total Assets | $292.8M |
| Total Liabilities | $29.7M |
| Equity | -$1.02B |
About Prokidney Corp
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Prokidney Corp is a publicly traded company under the ticker symbol PROK on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-07-01)